New Advances in Induced Airway and Lung Inflammation, and Intervention of Therapeutic Strategies

Dear Colleagues,

Many diseases, such as acute respiratory distress syndrome, asthma, cystic fibrosis, and chronic obstructive pulmonary disease, have one thing in common: lung inflammation. Animal and human inhalation of or exposure to smoking, air pollution, viruses, and bacteria can stimulate the generation of ROS, which are associated with airway and lung inflammatory diseases.

Respiratory inflammation is complicated by the involvement of various types of cells, pro-inflammatory cytokines, and other factors. In particular, cytokines, chemokines, and endotoxins have been implicated in the pathogenesis of pulmonary inflammation. Its pathogenesis is mediated through activation of various intracellular signaling components and transcription factors that lead to the expression of inflammatory proteins such as cytokines, chemokines, and adhesion molecules. Injurious environmental stimuli can access the lung either through the airways or the pulmonary and systemic circulations. The time course and intensity of responses in resident and circulating cells may be regulated by various inflammatory signaling that modulate both key inflammatory signaling transduction pathways and target proteins involved in airway and lung inflammation.

Yet, the complexity of the inflammation mechanism and combating inflammation have continued to create challenges. The interplay between oxidative stress and expression of inflammatory proteins induced by pro-inflammatory mediators leading to airway and lung inflammation needs to be further discussed. Knowledge of the mechanisms of oxidative stress regulation could lead to the pharmacological manipulation of antioxidants and anti-inflammation in airway and lung inflammation.

Thus, this Special Issue focuses on new advances on induced airway and lung inflammation, and intervention of therapeutic strategies. Research articles, new ideas, and development of potential interventions that manage and protect against airway and lung inflammation are welcome to enlighten, inspire, and provide a more comprehensive picture and understanding of this area of expertise.

Dr. Chuen-Mao Yang
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.